CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab
Category: #health  By Mateen Dalal  Date: 2020-02-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

CytoDyn files Phase 2 basket trial for cancer antagonist Leronlimab

CytoDyn Inc., announced that it has submitted a Phase 2 protocol with the U.S. Food and Drug Administration (FDA) for a basket trial under its cancer IND. The company can instantly start enrollment in this trial to offer therapy for around 22 various solid tumor cancers, such as brain-glioblastoma, melanoma, throat, stomach, lung, colon carcinoma, testicular, breast, ovarian, pancreas, uterine, bladder, among other indications. It is expecting to obtain preliminary outcomes on each subject within 3 to 4 weeks after the initial medication with leronlimab.  CytoDyn will continue to register patients in its metastatic breast cancer studies. 

The basket trial is a Phase 2 study with CCR5+ locally advanced or metastatic solid tumors including 30 subjects. Leronlimab will be administered subcutaneously as a weekly dose of 350 mg. Patients partaking in the trial will be allowed to receive and continue the standard-of-care chemotherapy as defined by the treating physician.

Bruce Patterson, M.D., Founder and Chief Executive Officer, IncellDx, an advisor and a diagnostic partner to CytoDyn, reportedly stated that the outcomes in patients with breast cancer have shown reduction in primary tumors, decrease in CTCs to zero, elimination or shrinking of metastatic lesions and remained stable for several weeks. Other trials demonstrated CTC levels in this cancer >5 and some as high as 20 per 4 mL of blood, he added.

Nader Pourhassan, Ph.D., Chief Executive Officer and President, CytoDyn, reportedly stated that if leronlimab  is able to demonstrate efficacy in this basket trial as the company has observed in the first 4 subjects in its MBC trials, the company will be able to file for another innovative therapy designation (BTD) for the multiple cancer indications evaluated in this study. Since the company started its cancer trials for mTNBC and compassionate usage and extended access for MBC, it has been receiving requests from subjects in the U.S. and overseas, he further added.

Source links:

https://www.cytodyn.com/newsroom/press-releases/detail/382/cytodyn-files-a-phase-2-basket-trial-with-leronlimab-pro

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Netsmart introduces unique mobile screening solution for COVID-19
Netsmart introduces unique mobile screening solution for COVID-19
By Mateen Dalal

In the face of the ongoing pandemic spread worldwide, that has disrupted businesses and turned normal lives upside down, companies have been striving to bring about innovative solutions that can ensure people to remain adequately and correctly inform...

First suspected cases of MIS-C under examination in South Korea
First suspected cases of MIS-C under examination in South Korea
By Mateen Dalal

Health authorities in South Korea have lately announced the ongoing medical examination of two children cited as suspected cases of a life-threatening syndrome associated with coronavirus. The two children are apparently the first suspected cases of ...

SpaceX raises $346 million a day before its debut astronaut mission
SpaceX raises $346 million a day before its debut astronaut mission
By Mateen Dalal

SpaceX recently raised about $346.2 million in the latest funding round just a day before it launches its latest manned spacecraft to the International Space Station. This launch of the first crewed mission from NASA's Space Center in Kennedy, Fl...